Prognostic significance of serum inflammation indices for different tumor infiltrative pattern types of gastric cancer

Table 2 Chi-square test analysis of the associations between the inflammation index and clinicopathological features

Characteristics	INFa			INFb			INFc
	SII ≤ 523.01 (119)	SII > 523.01 (64)	P value	PLR ≤ 134.02 (195)	PLR > 134.02 (136)	P value	PLR ≤ 134.02 (273)	PLR > 134.02 (175)	P value
Sex			0.443			0.979			0.489
Male	84 (70.6)	49 (76.6)		146 (74.9)	102 (75.0)		191 (70.0)	117 (66.9)
Female	35 (29.4)	15 (23.4)		49 (25.1)	34 (25.0)		82 (30.0)	58 (33.1)
Age (yr)			0.126			0.878			< 0.001
≤ 60	68 (57.1)	29 (45.3)		103 (52.8)	73 (53.7)		191 (70.0)	86 (49.1)
> 60	51 (42.9)	35 (54.7)		92 (47.2)	63 (46.3)		82 (30.0)	89 (50.9)
BMI			0.105			0.038			0.592
≤ 22.49	52 (43.7)	36 (56.3)		85 (43.6)	75 (55.1)		138 (50.5)	93 (53.1)
> 22.49	67 (56.3)	28 (43.7)		110 (56.4)	61 (44.9)		135 (49.5)	82 (46.9)
CEA			0.064			0.608			0.782
≤ 5 ng/mL	108 (90.8)	52 (81.2)		162 (83.1)	110 (80.9)		235 (86.1)	149 (85.1)
> 5 ng/mL	11 (9.2)	12 (18.8)		33 (16.9)	26 (19.1)		38 (13.9)	26 (14.9)
CA19-9			0.014			0.198			0.156
≤ 37 U/mL	112 (94.1)	53 (82.8)		168 (86.2)	110 (83.7)		246 (90.1)	150 (85.7)
> 37 U/mL	7 (5.9)	11 (17.2)		27 (13.8)	26 (16.3)		27 (9.9)	25 (14.3)
Borrmann type			0.005			0.051			0.454
0-2	71 (59.7)	22 (34.4)		84 (43.1)	72 (53.0)		80 (29.3)	45 (25.7)
3	40 (33.6)	34 (53.1)		92 (47.2)	46 (33.8)		141 (51.6)	101 (57.7)
4	8 (6.7)	8 (12.5)		19 (9.7)	18 (13.2)		52 (19.1)	29 (16.6)
Tumor diameter (mm)			< 0.001			< 0.001			< 0.001
≤ 50	95 (79.8)	31 (48.4)		131 (67.2)	63 (46.3)		172 (63.0)	75 (42.9)
> 50	24 (20.2)	33 (51.6)		64 (32.8)	73 (53.7)		101 (37.0)	100 (57.1)
Tumor location			0.992			0.051			0.423
Middle and upper third	16 (13.4)	9 (14.0)		57 (29.2)	40 (29.4)		62 (22.7)	44 (25.1)
Lower third	102 (85.7)	54 (84.4)		137 (70.3)	90 (66.2)		205 (75.1)	124 (70.9)
Entire stomach	1 (0.9)	1 (1.6)		1 (0.5)	6 (4.4)		6 (2.2)	7 (4.0)
Histological type			< 0.001			0.041			< 0.001
Well and medium differentiation	74 (62.2)	38 (59.4)		99 (50.8)	50 (36.8)		78 (28.6)	48 (27.4)
Poor differentiation	2 (1.7)	19 (30.0)		47 (24.1)	41 (30.1)		120 (43.9)	87 (49.7)
Others	18 (15.1)	7 (10.9)		49 (25.1)	45 (33.1)		75 (27.5)	40 (22.9)
pTNM stage			< 0.001			0.022			< 0.001
I	61 (51.3)	11 (17.2)		51 (26.2)	19 (14.0)		29 (10.6)	7 (4.0)
II	36 (30.2)	24 (37.5)		73 (37.4)	54 (39.7)		96 (35.2)	41 (23.4)
III	22 (18.5)	29 (45.3)		71 (36.4)	63 (46.3)		148 (54.2)	127 (72.6)
mLNR			0.019			0.290			0.001
≤ 0.07	84 (70.6)	34 (53.1)		109 (55.9)	68 (50.0)		131 (48.0)	56 (32.0)
> 0.07	35 (29.4)	30 (46.9)		86 (44.1)	68 (50.0)		142 (52.0)	119 (68.0)
Vascular infiltration			0.494			0.030			0.146
No	91 (76.5)	46 (71.9)		145 (74.4)	86 (63.2)		200 (73.3)	117 (66.9)
Yes	28 (23.5)	18 (28.1)		50 (25.6)	50 (36.8)		73 (26.7)	58 (33.1)
Nerve infiltration			0.098			0.592			0.238
No	85 (71.4)	38 (59.4)		119 (61.0)	79 (58.1)		159 (58.2)	92 (52.6)
Yes	34 (28.6)	26 (40.6)		76 (39.0)	57 (41.9)		114 (41.8)	83 (47.4)

Carcino-embryonic antigen and carbohydrate antigen 19-9 were according to the tumor marker examination. Tumor infiltrative pattern, tumor location, postsurgical tumor node metastasis stage, histological type, mLNR, vascular infiltration and nerve infiltration were according to the postoperative pathology report. Statistically significant P values are in bold (P < 0.05). INF: Tumor infiltrative pattern; INFa: Expansive growth type; INFb: Intermediate type; INFc: Infiltrative growth type; BMI: body mass index; CEA: Carcino-embryonic antigen; CA19-9: Carbohydrate antigen 19-9; mLNR: Metastatic lymph node ratio; pTNM: Postsurgical tumor node metastasis.